Similarly, the sphingosine-1-phosphate receptor agonist FTY720 (Fingolimod), which increases the functional activity of Tregs, inhibits atherosclerosis in Apoe−/− when orally administered at low doses by the expansion of Tregs, reduces effector T cell responses, and increases TGF-β expression [110]. The gene discussed is TGFB1; the disease is atherosclerosis.